

Please type a plus sign (+) inside this box → [+]

JAN 26 2004

PTO/SB08A (08-03)

U.S. Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

SHEET 1 of 1

| | |
|---|------------------|
| Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. | |
| Substitute for form 1449A/PTO | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | |
| (use as many sheets as necessary) | |
| SHEET 1 of 1 | |
| COMPLETE IF KNOWN | |
| Application Number | 10/699277 |
| Confirmation Number | |
| Filing Date | October 31, 2003 |
| First Named Inventor | Hird et al. |
| Group Art Unit | |
| Examiner Name | |
| Attorney Docket Number | 8473MR2 |

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See *Kind Codes of U.S. Patent Documents* at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 37 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

1. Type a plus sign (+) inside this box → [+].

JAN 26 2004

BEST AVAILABLE COPY

SUPPLEMENTAL PTO/SB08A (10-01)

Approved for use through 10/31/2002 OMB 0651-0031

Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

EX-137 1 of 1

| COMPLETE IF KNOWN | |
|------------------------|-------------------|
| Application Number | 10/083,218. |
| Confirmation Number | 8600 |
| Filing Date | February 26, 2002 |
| First Named Inventor | Bryn (NMN) Hird |
| Group Art Unit | |
| Examiner Name | |
| Attorney Docket Number | 8473M |

U. S. PATENT DOCUMENTS

| EXAMINER INITIALS | CRN No. | DOCUMENT NUMBER Number - Kind Code ³ (if known) | PUBLICATION DATE MM-DD-YYYY | NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT | PAGE, COLUMN, LINE WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR |
|-------------------|------------|---|--------------------------------|--|---|
| KW | 1 | US-5,650,222 | 07/22/1997 | DesMarais et al. | |
| KW | 2 | US-6,048,906 | 04/11/2000 | Kitagawa | |

FOREIGN PATENT DOCUMENTS

| EXAMINER INITIALS | CRN No. | FOREIGN PATENT DOCUMENT Country Code ⁴ Number ⁵ Kind Code ⁶ (if known) | PUBLICATION DATE MM-DD-YYYY | NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT | PAGE, COLUMN, LINE WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR |
|-------------------|------------|--|--------------------------------|--|---|
| KW | 3 | DE 199 42 365 A1 | 06/09/1999 | Beisel | |
| KW | 4 | EP 0901792 A1 | 03/17/1999 | Suweleck | |
| KW | 5 | EP 1214934 A2 | 09/06/2002 | Ration | |
| KW | 6 | WO 01/17377 A1 | 03/15/2001 | Beisel | |
| KW | 7 | WO 98/51408 A1 | 11/19/1998 | Chen | |

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

| | | |
|--|---|--|
| | MARKOVA EA: Treatment of Allimentary Obesity with Oxygen Foam" <i>Vrachebnoe Delo</i> , vol. 6, 1971, pages 108-108, XP001120225 ISSN: 0049-5804 Abstract | |
|--|---|--|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

³Applicant's unique citation designation number (optional). ⁴See Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ⁵Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁶For Japanese patent documents, the indication of the year of the Emperor must precede the serial number of the patent document. ⁷Kind of document by the appropriate symbols as indicated on the front under WIPO Standard ST.18 if possible. ⁸Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, D.C. 20231.

1 P E
Please type a plus sign (+) inside this box → [+]

JAN 26 2004

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

PTO/SB08A 10-01

Approved for use through 10/31/2002 OMB 0651-0031

Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

SHEET 1 of 2

COMPLETE IF KNOWN

| | |
|------------------------|-------------------|
| Application Number | 10/083,218 |
| Confirmation Number | 8600 |
| Filing Date | February 26, 2002 |
| First Named Inventor | Bryn (NMN) Hird |
| Group Art Unit | |
| Examiner Name | |
| Attorney Docket Number | 8374M |


U. S. PATENT DOCUMENTS

| EXAMINER INITIALS* | Cite No. ¹ | DOCUMENT NUMBER Number - Kind Code ² (If known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear |
|--------------------|-----------------------|---|--------------------------------|--|--|
| /KW/ | 1 | US-3,600,186 | 08/17/1971 | Mattson et al. | |
| /KW/ | 2 | US-3,688,763 | 09/05/1972 | Cromarty | |
| /KW/ | 3 | US-3,923,972 | 12/02/1975 | Fields et al. | |
| /KW/ | 4 | US-3,923,976 | 12/02/1975 | Regife Vega et al. | |
| /KW/ | 5 | US-3,980,968 | 09/14/1976 | Ma | |
| /KW/ | 6 | US-3,980,770 | 09/14/1976 | Ingelman et al. | |
| /KW/ | 7 | US-4,005,195 | 01/25/1977 | Jandacek | |
| /KW/ | 8 | US-4,039,489 | 08/02/1977 | Fletcher et al. | |
| /KW/ | 9 | US-4,211,765 | 08/08/1980 | Johnson et al. | |
| /KW/ | 10 | US-4223,023 | 09/16/1980 | Furda | |
| /KW/ | 11 | US-4,340,699 | 07/20/1982 | Grouiller | |
| /KW/ | 12 | US-4,401,682 | 08/30/1983 | Battista | |
| /KW/ | 13 | US-4,432,968 | 02/21/1984 | Page et al. | |
| /KW/ | 14 | US-4,598,089 | 07/01/1986 | Hadvary et al. | |
| /KW/ | 15 | US-5,331,015 | 07/19/1994 | DesMarais et al. | |
| /KW/ | 16 | US-5,447,953 | 09/05/1995 | Isler et al. | |
| /KW/ | 17 | US-5,451,416 | 09/19/1995 | Johnston et al. | |
| /KW/ | 18 | US-5,453,282 | 09/26/1995 | Kanauchi et al. | |
| /KW/ | 19 | US-5,534,284 | 07/09/1996 | Corrigan et al. | |
| /KW/ | 20 | US-5,603,950 | 02/18/1997 | Ratjen et al. | |
| /KW/ | 21 | US-6,030,953 | 02/29/2000 | Bailly et al. | |
| /KW/ | 22 | US-6,077,556 | 06/20/2000 | Letton et al. | |
| /KW/ | 23 | US-6,251,421 B1 | 06/26/2001 | Niazi | |

FOREIGN PATENT DOCUMENTS

| EXAMINER INITIALS* | Cite No. ¹ | FOREIGN PATENT DOCUMENT Country Code ³ , Number ⁴ Kind Code ⁵ (If known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear | T |
|--------------------|-----------------------|--|--------------------------------|--|---|---|
| /KW/ | 24 | WO 99/34787 A2 | 07/15/1999 | Mandeville et al. | | |
| /KW/ | 25 | WO 00/09122 A1 | 02/24/2000 | Hoffmann et al. | | |
| /KW/ | 26 | WO 00/09123 A1 | 02/24/2000 | Hoffmann et al. | | |
| /KW/ | 27 | WO 00/40247 A1 | 07/13/2000 | Alizm Therapeutics Ltd. | | |
| /KW/ | 28 | WO 00/40569 A1 | 07/13/2000 | Alizm Therapeutics Ltd. | | |
| /KW/ | 29 | WO 99/47183 A1 | 09/23/1999 | Procter & Gamble Co. | | |
| /KW/ | 30 | WO 01/53278 A1 | 07/26/2001 | Alizm Therapeutics Ltd. | | |
| /KW/ | 31 | EP 047217 B1 | 09/03/1997 | Ratjen | | |

/Kevin Weddington/ (04/27/2007)



Please type a plus sign (+) inside this box → +

JAN 26 2004

PTO/SB08A 10-01

Approved for use through 10/31/2002 OMB 0651-0031
Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

| | | | |
|-------------------------------|--|------------------------|-------------------|
| Substitute for form 1449A/PTO | | COMPLETE IF KNOWN | |
| | | Application Number | 10/083,218 |
| | | Confirmation Number | 8600 |
| | | Filing Date | February 26, 2002 |
| | | First Named Inventor | Bryn (NMN) Hird |
| | | Group Art Unit | |
| | | Examiner Name | |
| | | Attorney Docket Number | 8374M |

SHEET 2 of 2

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

FOREIGN PATENT DOCUMENTS

| EXAMINER INITIALS* | Cite No. ¹ | FOREIGN PATENT DOCUMENT | | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear | T ² |
|--------------------|-----------------------|---------------------------|---------------------|---|--|----------------|
| | | Country Code ³ | Number ⁴ | | | |
| /KW/ | 32 | JP | 56161319* | Shin-Etsu Chemical Indust. Co. Ltd. | | |
| /KW/ | 33 | JP | 2001048086* | Kyodo Kumiai Tsukuba Hitech Kenkyukai | | |

* English Abstract with Japanese Patent

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

| EXAMINER INITIALS* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
|--------------------|-----------------------|--|----------------|
| /KW/ | 34 | COMAI et al., "Antibesity Activity of Pluronic L-101", <u>International J. of Obesity</u> , 1980, pp. 33-42, Vol. 4. | |
| /KW/ | 35 | VOLPENHEIN et al., "Effect of Non-absorbable Lipid, Sucrose Polyester on the Absorption", <u>J. of Toxicology & Environmental Health</u> , 1980, pp. 679-683, Vol. 6. | |
| /KW/ | 37 | MUTTER et al., "Reduction in the Body Content of DDE in the Mongolian Gerbil Treated With Sucrose Polyester and Caloric Restriction", <u>Toxicology & Applied Pharmacology</u> , 1988, pp. 428-435, Vol. 92. | |
| /KW/ | 38 | CAVALIER et al., "Inhibition of Human Gastric and Pancreatic Lipases by Chiral Alkylphosphonates. A Kinetic Study With 1,2-didecanoyl-sn-glycerol Monolayer", <u>Chemistry and Physics of Lipids</u> , 1999, pp. 3-31, Vol. 100. | |
| /KW/ | 39 | GEUSAU et al., "Olestra Increases Faecal Excretion of 2,3,7,8-tetrachlorodibenzo-p-dioxin", <u>The Lancet</u> , 1999, pp. 1266-1267, Vol. 354. | |
| /KW/ | 40 | MOSER et al., "A Non-Absorbable Dietary Fat Substitute Enhances Elimination of Persistent Lipophilic Contamination in Humans", <u>Chemosphere</u> , 1999, pp. 1513-1521, Vol. 39 No. 9. | |
| /KW/ | 41 | LENGSFELD et al., "Effect of Orlistat and Chitosan on Faecal Fat Excretion in Young Healthy Volunteers", <u>Obesity Research</u> , November 1999, pp. 50S, Vol. 7, Suppl. 1. | |
| /KW/ | 42 | YAMAMOTO et al., "Anti-obesity Effects of Lipase Inhibitor CT-II, an Extract from Edible Herbs, Nomame Herba, on Rats Fed a High-fat diet", <u>International J. of Obesity</u> , 2000, pp. 758-764, Vol. 24. | |
| /KW/ | 43 | CHIOU et al., "Synthetic Routes and Lipase-Inhibiting Activity of Long-Chain α -Keto Amides", <u>Lipids</u> , 2001, pp. 535-542, Vol. 36, No. 5. | |
| /KW/ | 44 | HAN et al., "Anti-obesity Effects in Rodents of Dietary Teasaponin, a Lipase Inhibitor", <u>International J. of Obesity</u> , 2001, pp. 1459-1464, Vol. 25. | |

| EXAMINER | /Kevin Weddington/ (04/27/2007) | DATE CONSIDERED |
|----------|---------------------------------|-----------------|
| | | |

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 801.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, D.C. 20231.

Please type a plus sign (+) inside this box → []

JAN 26 2004

PTO/SB08A (10-01)

Approved for use through 10/31/2002 OMB 0651-0031
Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

SHEET 1 of 2

COMPLETE IF KNOWN

| | |
|------------------------|---|
| Application Number | 10/251376 |
| Confirmation Number | |
| Filing Date | 9/20/02 |
| First Named Inventor | Bryn (NMN) Hird & Ronald James Jandacek |
| Group Art Unit | |
| Examiner Name | |
| Attorney Docket Number | 8473MRL |

U. S. PATENT DOCUMENTS

| EXAMINER INITIALS ¹ | CITE No. ² | DOCUMENT NUMBER Number - Kind Code ³ (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear |
|--------------------------------|-----------------------|---|--------------------------------|--|--|
| /KW/ | 1 | US-3,600,188 | 08/17/1971 | Mattson et al. | |
| /KW/ | 2 | US-3,688,763 | 09/05/1972 | Cromarty | |
| /KW/ | 3 | US-3,923,972 | 12/02/1975 | Fields et al. | |
| /KW/ | 4 | US-3,923,978 | 12/02/1975 | Regife Vega et al. | |
| /KW/ | 5 | US-3,980,968 | 09/14/1976 | Ma | |
| /KW/ | 6 | US-3,980,770 | 09/14/1976 | Ingelman et al. | |
| /KW/ | 7 | US-4,005,195 | 01/25/1977 | Jandacek | |
| /KW/ | 8 | US-4,039,489 | 08/02/1977 | Fletcher et al. | |
| /KW/ | 9 | US-4,211,765 | 08/08/1980 | Johnson et al. | |
| /KW/ | 10 | US-4,223,023 | 09/16/1980 | Furda | |
| /KW/ | 11 | US-4,340,699 | 07/20/1982 | Grouiller | |
| /KW/ | 12 | US-4,401,682 | 08/30/1983 | Battista | |
| /KW/ | 13 | US-4,432,968 | 02/21/1984 | Page et al. | |
| /KW/ | 14 | US-4,698,089 | 07/01/1988 | Hadvary et al. | |
| /KW/ | 15 | US-5,331,015 | 07/19/1994 | DesMarais et al. | |
| /KW/ | 16 | US-5,447,953 | 09/05/1995 | Isler et al. | |
| /KW/ | 17 | US-5,451,416 | 09/19/1995 | Johnston et al. | |
| /KW/ | 18 | US-5,453,282 | 09/26/1995 | Kanauchi et al. | |
| /KW/ | 19 | US-5,534,284 | 07/09/1996 | Corrigan et al. | |
| /KW/ | 20 | US-5,603,950 | 02/18/1997 | Ratjen et al. | |
| /KW/ | 21 | US-6,030,953 | 02/29/2000 | Bailey et al. | |
| /KW/ | 22 | US-6,077,558 | 06/20/2000 | Letton et al. | |
| /KW/ | 23 | US-6,251,421 B1 | 06/26/2001 | Niazi | |

FOREIGN PATENT DOCUMENTS

| EXAMINER INITIALS ¹ | CITE No. ² | FOREIGN PATENT DOCUMENT Country Code ³ Number ⁴ Kind Code ⁵ (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear | + |
|--------------------------------|-----------------------|---|--------------------------------|--|--|---|
| /KW/ | 24 | WO 89/34787 A2 | 07/15/1999 | Mandeville et al. | | |
| /KW/ | 25 | WO 00/09122 A1 | 02/24/2000 | Hoffmann et al. | | |
| /KW/ | 26 | WO 00/09123 A1 | 02/24/2000 | Hoffmann et al. | | |
| /KW/ | 27 | WO 00/40247 A1 | 07/13/2000 | Alizme Therapeutics Ltd. | | |
| /KW/ | 28 | WO 00/40569 A1 | 07/13/2000 | Alizme Therapeutics Ltd. | | |
| /KW/ | 29 | WO 99/47183 A1 | 09/23/1999 | Procter & Gamble Co. | | |
| /KW/ | 30 | WO 01/53278 A1 | 07/26/2001 | Alizme Therapeutics Ltd. | | |
| /KW/ | 31 | EP 047217 B1 | 09/03/1997 | Ratjen | | |

/Kevin Weddington/ (04/27/2007)

BEST AVAILABLE COPY

case type @ plus sign (+) inside this box → []

JAN 28 2004

PTO/SB08A (10-01)

Approved for use through 10/31/2002 OMB 0651-0031

Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number
Substitute for form 1449A/PTOINFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(use as many sheets as necessary)

SHEET 2 of 2

COMPLETE IF KNOWN

| | |
|------------------------|---|
| Application Number | 10/251376 |
| Confirmation Number | |
| Filing Date | 9/20/02 |
| First Named Inventor | Bryn (NMN) Hird & Ronald James Jandacek |
| Group Art Unit | |
| Examiner Name | |
| Attorney Docket Number | 8473MRL |

FOREIGN PATENT DOCUMENTS

| EXAMINER INITIALS* | | FOREIGN PATENT DOCUMENT | | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Column, Lines Where Relevant Passages or Relevant Figures Appear | * |
|--------------------|----|-------------------------|--|--------------------------------|--|--|---|
| /KWI | 32 | JP 56161318* | | 12/11/1981 | Shin-Etsu Chemical Indust. Co. Ltd. | | |
| /KWI | 33 | JP 2001048086* | | 02/20/2001 | Kyodo Kumai Tsukuba Hitech Kenkyukai | | |

* English Abstract with Japanese Patent

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

| EXAMINER INITIALS* | | Publ. No.* | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | * |
|--------------------|----|--|---|---|
| /KWI | 34 | COMAI et al., "Antibesity Activity of Pluronic L-101", <i>International J. of Obesity</i> , 1980, pp. 33-42, Vol. 4. | | |
| /KWI | 35 | VOLPENHEIN et al., "Effect of Non-absorbable Lipid, Sucrose Polyester on the Absorption", <i>J. of Toxicology & Environmental Health</i> , 1980, pp. 679-683, Vol. 6. | | |
| /KWI | 37 | MUTTER et al., "Reduction in the Body Content of DDE in the Mongolian Gerbil Treated With Sucrose Polyester and Caloric Restriction", <i>Toxicology & Applied Pharmacology</i> , 1988, pp. 428-435, Vol. 82. | | |
| /KWI | 38 | CAVALIER et al., "Inhibition of Human Gastric and Pancreatic Lipases by Chiral Alkylphosphonates. A Kinetic Study With 1,2-didecanoyl-sn-glycerol Monolayer", <i>Chemistry and Physics of Lipids</i> , 1999, pp. 3-31, Vol. 100. | | |
| /KWI | 39 | GEUSAU et al., "Olestra Increases Faecal Excretion of 2,3,7,8-tetrachlorodibenzo-p-dioxin", <i>The Lancet</i> , 1999, pp. 1266-1267, Vol. 354. | | |
| /KWI | 40 | MOSER et al., "A Non-Absorbable Dietary Fat Substitute Enhances Elimination of Persistent Lipophilic Contamination in Humans", <i>Chemosphere</i> , 1999, pp. 1513-1521, Vol. 39 No. 9. | | |
| /KWI | 41 | LENGSFELD et al., "Effect of Orlistat and Chitosan on Faecal Fat Excretion in Young Healthy Volunteers", <i>Obesity Research</i> , November 1999, pp. 509, Vol. 7, Suppl. 1. | | |
| /KWI | 42 | YAMAMOTO et al., "Anti-obesity Effects of Lipase Inhibitor CT-II, an Extract from Edible Herba, Nomame Herba, on Rats Fed a High-fat diet", <i>International J. of Obesity</i> , 2000, pp. 758-764, Vol. 24. | | |
| /KWI | 43 | CHIOU et al., "Synthetic Routes and Lipase-Inhibiting Activity of Long-Chain α -Keto Amides", <i>Lipids</i> , 2001, pp. 535-542, Vol. 36, No. 5. | | |
| /KWI | 44 | HAN et al., "Anti-obesity Effects in Rodents of Dietary Teasaponin, a Lipase Inhibitor", <i>International J. of Obesity</i> , 2001, pp. 1459-1464, Vol. 25. | | |

EXAMINER /Kevin Weddington/ (04/27/2007) DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Applicant's unique citation designation number (optional). ²See Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burd n Hour Statement: This form is estimated to tak 2.0 hours to complete. Time will vary d pending upon the needs of the individual case. Any comments n the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, D.C. 20231.